nanosymposium - Society for Neuroscience

9:00 I2 347.14 P73 and Alzheimer disease are not
associated in a transgenic model or in human cohorts. D.
VERGOTE*; B. VARDARAJAN; M. LOGUE; J. YANG; E.
ROGAEVA; J. LEE; R. CHENG; M. GHANI; B. SHI; C. T.
BALDWIN; S. KAR; R. MAYEUX; P. FRASER; L. A. FARRER;
D. WESTAWAY. Univ. Alberta, Boston Univ. Sch. of Med.,
Univ. of Toronto, Columbia Univ.
10:00 I3 347.15 Map tau mediates LTP inhibition after low
frequency stimuli in wild type mouse brain. T. KIMURA*; S.
YAMASHITA; M. MURAYAMA; T. MIZOROKI; A. TAKASHIMA.
RIKEN.
11:00 I4 347.16 Exposure of the N-terminal phosphataseactivating
domain of tau: Implications in axonal transport
dysfunction and disease pathogenesis. N. M. KANAAN*; G.
MORFINI; Y. FU; S. BRADY; L. BINDER. Northwestern Univ.,
Univ. of Illinois at Chicago.
8:00 I5 347.17 Characterization of tau oligomers and the
role of Hsp70 in tau oligomerization. K. R. PATTERSON*;
N. M. KANAAN; M. J. GLUCKSMAN; T. C. GAMBLIN; L. I.
BINDER. Northwestern Univ., RFUMS/Chicago Med. Sch.,
Univ. of Kansas.
9:00 I6 347.18 • Accurate measurement of CSF tau in
transgenic mice. D. M. BARTEN*; L. YANG; G. CADELINA; N.
HOQUE; L. DECARR; V. GUSS; S. SANKARANARAYANAN;
J. MEREDITH; M. AHLIJANIAN; C. F. ALBRIGHT. Bristol-
Myers Squibb.
10:00 I7 347.19 Pseudohyperphosphorylation mutations
in tau isoforms affect polymerization and interaction with
microtubules. B. COMBS*; K. VOSS; T. C. GAMBLIN. Univ. of
Kansas.
11:00 I8 347.20 Progression of tau pathology in cholinergic
nucleus basalis neurons in MCI and AD. L. C. VANA*; N.
M. KANAAN; I. C. UGWU; E. J. MUFSON; L. I. BINDER.
Northwestern Univ., Rush Univ.
8:00 I9 347.21 Increased tau pathology in type 2
diabetes mouse model. N. EL KHOURY*; F. MARCOUILLER;
M. PAPON; F. MORIN; E. PLANEL*. Ctr. Hospitalier De
L’Université Laval.
9:00 I10 347.22 Heat shock protein 70 alters tau isoform
functions in vitro. K. VOSS*; B. COMBS; T. C. GAMBLIN.
Univ. of Kansas.
10:00 I11 347.23 Mitochondrial mislocalization in a
mouse model of tauopathy (rTg4510). K. J. KOPEIKINA*;
R. PITSTICK; G. A. CARLSON; T. L. SPIRES-JONES; B.
T. HYMAN. Boston Univ. Sch. of Med., MassGeneral Inst.
for Neurodegenerative Dis. at Massachusetts Gen. Hosp.,
McLaughlin Res. Inst., Harvard Med. Sch.
11:00 I12 347.24 Role of tau function in cognitive
deficits in Alzheimer model mice. D. J. GANT; F. YANG; M.
ALAVERDYAN; Q. MA; G. M. COLE; S. A. FRAUTSCHY*.
UCLA, Cedars-Sinai Med. Ctr.
8:00 I13 347.25 • Synaptic mitochondria from a tauopathy
model of AD have increased mass and membrane potential.
K. HENKINS*; M. ALAVERDYAN; S. FRAUTSCHY; G. COLE;
C. MILLER; H. VINTERS; K. GYLYS. UCLA, Sepulveda
VAMC GRECC, UCLA Sch. of Med. and Sepulveda VAMC
GRECC, Keck USC Sch. of Med., UCLA Sch. of Nursing and
Brain Res. Inst.
9:00 I14 347.26 Spread of tauopathy and its functional
impacts in transgenic mice with entorhinal cortex restricted
expression of mutant human tau. L. LIU*; S. SMALL; K. DUFF.
Columbia Univ.
• Indicated a real or perceived conflict of interest, see page 157 for details.
� Indicates a high school or undergraduate student presenter.
10:00 I15 347.27 • Biochemical characterisation of tau
pathology in the P301S mouse model. S. J. GLOVER*; J.
WOLAK; T. K. MURRAY; C. V. CELLA; R. PURCELL; N.
BUCKNER; M. J. O’NEILL; V. LAKICS; I. LAVENIR; M.
GOEDERT; P. DAVIES; M. L. HUTTON; P. G. SZEKERES. Eli
Lilly and Co. Ltd, MRC, Albert Einstein Col. of Med.
11:00 I16 347.28 • Tau histopathology and
neurodegeneration in rTg4510 mice depend on genetic
background. J. N. MARCUS*; A. HUGHES; R. KENNAN;
C. WOLFFE; M. PEARSON; X. WANG; J. RENGER; M.
SAVAGE. Merck Res. Labs.
8:00 I17 347.29 • Exploring tauopathies in transgenic
zebrafish by in vivo imaging. D. PAQUET; G. PLUCINSKA;
L. GODINHO; T. MISGELD; R. BHAT; E. MANDELKOW;
B. SCHMID; C. HAASS*. DZNE - German Ctr. for
Neurodegenerative Dis., TU Munich, AstraZeneca R&D, Max-
Planck Unit for Structural Mol. Biol. at DESY, Adolf Butenandt
Inst, LMU.
9:00 I18 347.30 • Prominent neuroinflammation in the
Tg4510 tauopathy model revealed by transcriptional profiling.
J. P. CORRADI*; L. YANG; N. HOQUE; P. POUNDSTONE;
V. PATEL; L. DECARR; C. ANDORFER; A. M. CACACE; D.
BARTEN. Bristol-Myers Squibb Co., Mayo Clin.
POSTER
348. Aging: Animals and humans
Theme C: Disorders of the Nervous System
Mon. 8:00 AM — San Diego Convention Center, Halls B-H
8:00 I19 348.1 • Serum antibody biomarkers for
Alzheimer’s disease. D. C. GERMAN*; R. DIAZ-ARRASTIA;
M. REDDY; J. WILSON; R. WILSON; T. KODADEK. U Texas
Southwestern Med. Cntr., The Scripps Res. Inst.
9:00 I20 348.2 GAMMA suite: an open source cross
platform Bayesian data-mining software package for
neuroimaging structure-function analysis. R. CHEN;
E. HERSKOVITS*. Univ. of Pennsylvania, university of
pennsylvania.
10:00 I21 348.3 Influence of viral vector-mediated delivery
of superoxide dismutase and catalase to the hippocampus
on spatial learning and memory over the course of aging. W.
LEE*; A. KUMAR; A. RANI; J. HERRERA; T. FOSTER. Univ.
Florida.
11:00 I22 348.4 Caudate atrophy & its clinical correlates in
400 Alzheimer’s disease, MCI, & healthy elderly subjects. S.
K. MADSEN*; A. J. HO; X. HUA; P. S. SAHARAN; C. R. JACK
JR.; M. W. WEINER; A. W. TOGA; P. M. THOMPSON. UCLA,
Mayo Clin. Col. of Med., UCSF.
8:00 I23 348.5 Hysterectomy is associated with increased
brain ferritin iron levels. T. A. TISHLER*; E. P. RAVEN; P.
H. LU; C. P. AMAR; N. R. DETORE; L. L. ALTSHULER; G.
BARTZOKIS. UCLA.
9:00 I24 348.6 Common Alzheimer’s disease risk variant
within the CLU gene affects white matter microstructure in
young adults. M. N. BRASKIE*; N. JAHANSHAD; J. L. STEIN;
M. BARYSHEVA; K. L. MCMAHON; G. I. DE ZUBICARAY; N.
G. MARTIN; M. J. WRIGHT; J. M. RINGMAN; A. W. TOGA;
P. M. THOMPSON. Univ. California Los Angeles, Univ. of
Queensland, Queensland Inst. of Med. Res.
Neuroscience 2010 | Monday AM | 23
Mon. AM